Anti Inflammatory News and Research

RSS

Oats Nutrition and Technology: A comprehensive textbook from Quaker

Considered the most comprehensive and up-to-date textbook about the life cycle of oats, Oats Nutrition and Technology was released from Wiley-Blackwell publishers, and is now available at all major online publishing websites, including Amazon.com.

2 Apr 2014

Research uncovers link between diet and blood cell markers of heart attack associated inflammation

New research further illuminates the heart-healthy benefits of the Mediterranean diet, tying the eating plan to lower levels of platelets and white blood cells, two markers of inflammation. Inflammation has an association with greater risk of heart attack and stroke.

1 Apr 2014

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.

31 Mar 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

26 Mar 2014

North Coast Medical announces acquisition of ActivaTek

North Coast Medical, Inc., a manufacturer and global supplier of physical rehabilitation medical products, today announced the acquisition of Salt Lake City, Utah-based ActivaTek, Inc., a privately held manufacturer of transdermal iontophoretic devices.

25 Mar 2014

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown.

25 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

Simvastatin may slow progression of multiple sclerosis

Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.

20 Mar 2014

Research on diverse health benefits of oats in protecting heart

Eleven top scientists from around the globe presented the latest findings on the powerful compounds found in oats in a scientific session titled, Physicochemical Properties and Biological Functionality of Oats, at the 247th Annual Conference of the American Chemical Society in Dallas, TX

17 Mar 2014

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.

17 Mar 2014

Scientists develop new water purifier that could work with sunlight

Sunlight plus a common titanium pigment might be the secret recipe for ridding pharmaceuticals, pesticides and other potentially harmful pollutants from drinking water.

17 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Molecular substance that occurs naturally in humans reduces brain damage after acute stroke

A molecular substance that occurs naturally in humans and rats was found to "substantially reduce" brain damage after an acute stroke and contribute to a better recovery, according to a newly released animal study by researchers at Henry Ford Hospital.

12 Mar 2014

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients.

11 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Findings provide new target for development of novel therapies to manage chronic pain

Scientists have shown for the first time that the abnormalities in the way the brain experiences pain may be to blame for the chronic pain suffered by osteoarthritis patients.

10 Mar 2014

Research to identify exact mechanisms behind preterm birth and fetal brain injury

An inflammatory protein that triggers a pregnant mouse's immune response to an infection or other disease appears to cause brain injury in her fetus, but not the premature birth that was long believed to be linked with such neurologic damage in both rodents and humans, new Johns Hopkins-led research suggests.

6 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Anti Inflammatory News and Research

Oats Nutrition and Technology: A comprehensive textbook from Quaker

Research uncovers link between diet and blood cell markers of heart attack associated inflammation

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

North Coast Medical announces acquisition of ActivaTek

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Simvastatin may slow progression of multiple sclerosis

Research on diverse health benefits of oats in protecting heart

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Scientists develop new water purifier that could work with sunlight

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Molecular substance that occurs naturally in humans reduces brain damage after acute stroke

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Antares Pharma announces launch of OTREXUP to Dermatologists

Findings provide new target for development of novel therapies to manage chronic pain

Research to identify exact mechanisms behind preterm birth and fetal brain injury

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News